TRPV6 and cancer: Derivatives of the small molecule (4-phenylcyclohexyl) piperazine (PCHPDs) are TRPV6 channel blocking drugs with additional weaker affinity for the vanilloid site (Bhardwaj et al., 2020); drugs that inhibit TRPV6 are of particularly strong clinical significance, given TRPV6’s overexpression in several types of cancer cells (Stewart, 2020).